Medicare Part B Premium Hike To Accommodate Alzheimer’s Drug Costs Is Premature – Sen. Wyden
Executive Summary
Unprecedented increase spotlights how drug costs could drain Medicare, but Senate Finance Committee chair, a prominent pricing critic, urges waiting until Alzheimer’s coverage policy comes out before raising premiums so high. Draft policy is on track for January release, CMS official says.
You may also be interested in...
Sen. Wyden Using Califf Nomination To Extract Accelerated Approval Reforms
The unexpectedly tight fight to get Robert Califf confirmed as FDA commissioner is giving lawmakers additional leverage to extract commitments. However, the Senate Finance Chair may be overestimating FDA’s ability to swiftly pull accelerated approvals without new legislation.
Aduhelm & Medicare: HHS Reconsideration Of Premium Hike May Ease Blowback On Coverage
Biogen’s Alzheimer’s drug may not cause as much of a financial headache to American seniors as expected, which could dampen criticism of Medicare’s upcoming coverage determination. But questions remain about what exactly HHS will be able to do about Part B premiums.
Woodcock: High Prices Create Problems For Entire Accelerated Approval Program
Acting FDA commissioner suggests a primary reason for outrage over accelerated approvals is the high costs of certain medications despite their unproven clinical benefits, an issue that is outside of the agency’s purview. Health policy experts says FDA shouldn’t be left off the hook that easily.